Offen WW - Search Results

1

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Bodick NC, et al. Among authors: offen ww. Arch Neurol. 1997 Apr;54(4):465-73. doi: 10.1001/archneur.1997.00550160091022. Arch Neurol. 1997. PMID: 9109749 Clinical Trial.

2

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. Bodick NC, et al. Among authors: offen ww. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S16-22. Alzheimer Dis Assoc Disord. 1997. PMID: 9339268 Clinical Trial.

3

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.

Satlin A, Bodick N, Offen WW, Renshaw PF. Satlin A, et al. Among authors: offen ww. Am J Psychiatry. 1997 Oct;154(10):1459-61. doi: 10.1176/ajp.154.10.1459. Am J Psychiatry. 1997. PMID: 9326834 Clinical Trial.

4

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Veroff AE, et al. Among authors: offen ww. Alzheimer Dis Assoc Disord. 1998 Dec;12(4):304-12. doi: 10.1097/00002093-199812000-00010. Alzheimer Dis Assoc Disord. 1998. PMID: 9876958 Clinical Trial.

5

A simple stopping rule for declaring treatment ineffectiveness in clinical trials.

Enas GG, Offen WW. Enas GG, et al. Among authors: offen ww. J Biopharm Stat. 1993 Mar;3(1):13-22. doi: 10.1080/10543409308835046. J Biopharm Stat. 1993. PMID: 8485534

6

A new classification approach for comparing two active treatments when there is no prior projection on which one is better.

Qu Y, Liu R, Dmitrienko A, Offen W. Qu Y, et al. Stat Med. 2011 Dec 30;30(30):3488-95. doi: 10.1002/sim.4402. Epub 2011 Nov 15. Stat Med. 2011. PMID: 22086771

7

Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.

Dmitrienko A, Offen WW, Westfall PH. Dmitrienko A, et al. Among authors: offen ww. Stat Med. 2003 Aug 15;22(15):2387-400. doi: 10.1002/sim.1526. Stat Med. 2003. PMID: 12872297

8

Challenge of multiple co-primary endpoints: a new approach.

Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W. Chuang-Stein C, et al. Stat Med. 2007 Mar 15;26(6):1181-92. doi: 10.1002/sim.2604. Stat Med. 2007. PMID: 16927251

9

Overview of multiple testing methodology and recent development in clinical trials.

Wang D, Li Y, Wang X, Liu X, Fu B, Lin Y, Larsen L, Offen W. Wang D, et al. Contemp Clin Trials. 2015 Nov;45(Pt A):13-20. doi: 10.1016/j.cct.2015.07.014. Epub 2015 Jul 22. Contemp Clin Trials. 2015. PMID: 26210511 Review.

10

Optimizing Graphical Procedures for Multiplicity Control in a Confirmatory Clinical Trial via Deep Learning.

Zhan T, Hartford A, Kang J, Offen W. Zhan T, et al. Stat Biopharm Res. 2022;14(1):92-102. doi: 10.1080/19466315.2020.1799855. Epub 2020 Aug 24. Stat Biopharm Res. 2022. PMID: 35401935 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters